title:: The Seven Characteristics of Leading AI-Native Startups in Healthcare & Life Sciences

publisher:: Amazon Web Services

people:: Razvan Ionasec, Daniel Rabina

organization:: Amazon Web Services (AWS), Slush

domain:: Healthcare, Life Sciences, Artificial Intelligence, Startups, Venture Capital

link:: https://aws.amazon.com/aws-startups/insights/#the-seven-characteristics-of-leading-ai-native-startups-in-healthcare-and-life-sciences

blogsfeatured

Summary

AI has collapsed development cycles in Healthcare & Life Sciences from years to months, so building fast no longer sets a startup apart. This AWS report, launched on 19 November 2026 at Slush in Helsinki, examines where the advantage now comes from. Drawing on interviews with leading investors (including Bessemer Venture Partners, Sofinnova, ELAIA, Speedinvest and BACKED VC), operators and AWS specialists, it finds the answer is consistent across TechBio and HealthTech: the edge lies in what a company builds around the AI. That means proprietary science and data, scientific and clinical evidence, workflow integration, trusted relationships, and the ability to learn continuously from every experiment, deployment and customer.

The report sets out what has changed for HCLS startups, the seven characteristics of the companies best positioned to lead, and Europe’s structural opportunity to capture more of the value it creates.

My contribution

I contributed to the report as Head of Healthcare EMEA at AWS:

Prototypes are becoming extremely cheap. They cost you minutes and a handful of tokens. But how fast can you actually validate those prototypes in the market? Can you still create value if we swap models in and out? Make sure you’re protected by that: have your own data, your own evaluations, your own traces, and be able to iterate on them. That in itself will create the next level of IP.

Read the report


Cover image: © Amazon Web Services, from the report.